Lyell Immunopharma, Inc. (LYEL) — Financial statements
Income statement, balance sheet, and cash flow for Lyell Immunopharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.04↓41.0% | 0.06↓53.1% | 0.13↓99.8% | 85↑695.1% | 11 | |
| Cost of Revenue | 12 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -12↓18957.4% | 0.06↓53.1% | 0.13↓99.8% | 85↑695.1% | 11 | |
| Operating Expenses | ||||||
| R&D Expenses | 159↓7.5% | 172↓6.2% | 183↑14.9% | 159↑14.8% | 139 | |
| General & Administrative Expenses | 45↓13.3% | 52↓22.3% | 67↓42.9% | 117↑31.7% | 89 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 45↓13.3% | 52↓22.3% | 67↓42.9% | 117↑31.7% | 89 | |
| Other Expenses | -12↓108.5% | 135↑4944.9% | -3↑41.3% | -5↓104.6% | -2 | |
| Operating Expenses | 192↓46.4% | 359↑45.2% | 247↓9.1% | 272↑20.5% | 225 | |
| Total Costs & Expenses | 204↓43.2% | 359↑45.2% | 247↓9.1% | 272↑20.5% | 225 | |
| Operating Results | ||||||
| Operating Income | -204↑43.2% | -359↓45.2% | -247↓32.0% | -187↑12.9% | -215 | |
| Depreciation & Amortization | 12↓41.2% | 20↓3.1% | 20↑12.4% | 18↑32.3% | 14 | |
| EBITDA | -192↑4.2% | -201↑11.5% | -227↓34.1% | -169↑16.0% | -201 | |
| EBIT | -204↑7.5% | -220↑10.8% | -247↓32.0% | -187↑12.9% | -215 | |
| Interest & Other Income | ||||||
| Net Interest Income | 13↓45.7% | 24↑2.6% | 23↑232.5% | 7↑505.4% | 1 | |
| Interest Income | 13↓45.7% | 24↑2.6% | 23↑232.5% | 7↑505.4% | 1 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -138 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -71↓548.4% | 16↑27.4% | 12↑214.1% | 4↑111.1% | -35 | |
| Income Before Tax | -274↑20.0% | -343↓46.2% | -235↓28.1% | -183↑26.8% | -250 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -274↑20.0% | -343↓46.2% | -235↓28.1% | -183↑26.8% | -250 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -274↑20.0% | -343↓46.2% | -235↓28.1% | -183↑26.8% | -250 | |
| Bottom-Line Net Income | -274↑20.0% | -343↓46.2% | -235↓28.1% | -183↑26.8% | -250 | |
| EPS (Basic) | -16.06↓1126.0% | -1.31↓40.1% | -0.93↓26.1% | -0.74↑28.1% | -1.03 | |
| EPS (Diluted) | -16.06↓1126.0% | -1.31↓40.1% | -0.93↓26.1% | -0.74↑28.1% | -1.03 | |
| Weighted Average Shares | 17↑30.7% | 13↑4.2% | 13↑1.6% | 12↑1.8% | 12 | |
| Weighted Average Diluted Shares | 17↑30.7% | 13↑4.2% | 13↑1.6% | 12↑1.8% | 12 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.